Molecule restores cognition and memory in Alzheimer's disease mouse study

UCLA Health researchers have identified and synthesized a molecule, DDL-920, that was shown to restore cognitive functions in Alzheimer's disease model mice by jump-starting the brain's memory circuitry. While current FDA-approved drugs like lecanemab and aducanumab remove harmful plaque and slow cognitive decline, they do not restore memory. DDL-920, however, offers a novel treatment by targeting fast-firing neurons essential for memory and cognition.

• DDL-920 may revitalize memory for Alzheimer's and depression.
• Molecule differs from drugs like lecanemab, aducanumab.
• Targets fast-firing neurons critical for cognition.
• Could have implications for other conditions.
• More research needed for human efficacy, safety.